Literature DB >> 15034022

Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

David H Munn1, Madhav D Sharma, Andrew L Mellor.   

Abstract

Human monocyte-derived dendritic cells (DCs) are capable of expressing the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO), which allows them to suppress Ag-driven proliferation of T cells in vitro. In DCs that express IDO, the activity of the enzyme is tightly regulated, with the protein being constitutively expressed, but functional activity requiring an additional set of triggering signals supplied during Ag presentation. We now show that triggering of functional IDO obligately requires ligation of B7-1/B7-2 molecules on the DCs by CTLA4/CD28 expressed on T cells. When this interaction was disrupted, IDO remained in the inactive state, and the DCs were unable to inhibit T cell proliferation. Inhibition could be fully restored by direct Ab-mediated cross-linking of B7-1/B7-2. Although both CD4(+) and CD8(+) T cells were susceptible to inhibition once IDO was induced, the ability to trigger functionally active IDO was strictly confined to the CD4(+) subset. Thus, the ability of CD4(+) T cells to induce IDO activity in DCs allowed the CD4(+) population to dominantly inhibit proliferation of the CD8(+) population via the bridge of a conditioned DC. We hypothesize that IDO activation via engagement of B7-1/B7-2 molecules on DCs, specifically, engagement by CTLA4 expressed on regulatory CD4(+) T cells, may function as a physiologic regulator of T cell responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034022     DOI: 10.4049/jimmunol.172.7.4100

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  154 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  Changing the energy of an immune response.

Authors:  Meghan M Delmastro-Greenwood; Jon D Piganelli
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

3.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors:  Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

4.  Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo.

Authors:  N M Rogers; S Kireta; P T H Coates
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

5.  Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

Authors:  Madhav D Sharma; Babak Baban; Phillip Chandler; De-Yan Hou; Nagendra Singh; Hideo Yagita; Miyuki Azuma; Bruce R Blazar; Andrew L Mellor; David H Munn
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Regulatory T-cell markers, indoleamine 2,3-dioxygenase, and virus levels in spleen and gut during progressive simian immunodeficiency virus infection.

Authors:  Adriano Boasso; Monica Vaccari; Anna Hryniewicz; Dietmar Fuchs; Janos Nacsa; Valentina Cecchinato; Jan Andersson; Genoveffa Franchini; Gene M Shearer; Claire Chougnet
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

Review 7.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

8.  Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.

Authors:  Alexander J Muller; Madhav D Sharma; Phillip R Chandler; James B Duhadaway; Mary E Everhart; Burles A Johnson; David J Kahler; Jeanene Pihkala; Alejandro Peralta Soler; David H Munn; George C Prendergast; Andrew L Mellor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-24       Impact factor: 11.205

Review 9.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.